Even though the DAISY trial enrolled patients based on HER2 IHC assessments and did not focus on detailed information on HER2 copy number and HER2 CEP/17 ratios, it may be interesting to investigate HER2 amplification levels in future studies since the ISH analysis is essential for clinical treatment decisions in HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.